Petros Pharmaceuticals, Inc.

Petros Pharmaceuticals, Inc. ’s overall strong results from a self-selection study featuring its digital app for OTC access to its Stendra (avanafil) erectile dysfunction drug include particularly str

The Food and Drug Administration’s “additional conditions of nonprescription use” proposed rule for making more drug ingredients available OTC in the US portends introducing additional labeling obviou

Erectile dysfunction drugs haven’t generated the most noise as likely OTC switch candidates with the US Food and Drug Administration moving toward making digital labeling part of its regulatory framew

Petros Pharmaceuticals, Inc. expects a recent label comprehension study to move it closer to an Rx-to-OTC switch of its Stendra erectile dysfunction drug, a project it has increased research spending